NSEI:BALPHARMA

Stock Analysis Report

Executive Summary

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

Snowflake

Fundamentals

Unattractive dividend payer with imperfect balance sheet.

Risks

  • Bal Pharma has significant price volatility in the past 3 months.
  • Bal Pharma is not covered by any analysts.

Share Price & News

How has Bal Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-16.9%

NSEI:BALPHARMA

-1.7%

IN Pharmaceuticals

-0.7%

IN Market


1 Year Return

-52.0%

NSEI:BALPHARMA

-21.7%

IN Pharmaceuticals

-12.1%

IN Market

BALPHARMA underperformed the Pharmaceuticals industry which returned -21.7% over the past year.

BALPHARMA underperformed the Market in India which returned -12.1% over the past year.


Share holder returns

BALPHARMAIndustryMarket
7 Day-16.9%-1.7%-0.7%
30 Day-21.7%-3.2%-4.6%
90 Day-29.9%-6.1%-4.3%
1 Year-51.6%-52.0%-21.1%-21.7%-10.3%-12.1%
3 Year-51.6%-53.1%-25.1%-26.5%18.9%12.8%
5 Year-28.1%-32.3%-6.0%-8.7%37.6%24.7%

Price Volatility Vs. Market

How volatile is Bal Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bal Pharma undervalued based on future cash flows and its price relative to the stock market?

0.86x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Bal Pharma's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Bal Pharma's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Bal Pharma is loss making, we can't compare its value to the IN Pharmaceuticals industry average.

Bal Pharma is loss making, we can't compare the value of its earnings to the India market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Bal Pharma, we can't assess if its growth is good value.


Price Based on Value of Assets

Bal Pharma is good value based on assets compared to the IN Pharmaceuticals industry average.


Next Steps

Future Growth

How is Bal Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.7%

Forecasted Pharmaceuticals industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bal Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bal Pharma performed over the past 5 years?

-36.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Bal Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Bal Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Bal Pharma's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Bal Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

Bal Pharma used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if Bal Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Bal Pharma's financial position?


Financial Position Analysis

Bal Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Bal Pharma's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Bal Pharma's level of debt (214.6%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (106% vs 214.6% today).

Operating cash flow is negative therefore debt is not well covered.

Bal Pharma is making a loss, therefore interest payments are not well covered by earnings.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.4x debt.


Next Steps

Dividend

What is Bal Pharma's current dividend yield, its reliability and sustainability?

2.48%

Current Dividend Yield


Upcoming Dividend Payment

Purchase Bal Pharma before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield and Payments Analysis

Bal Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.63%).

Bal Pharma's dividend is below the markets top 25% of dividend payers in India (2.52%).

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

The company is paying a dividend however it is incurring a loss.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Bal Pharma's salary, the management and board of directors tenure and is there insider trading?

7.3yrs

Average board tenure


CEO

Akash Mathur

2.9yrs

Tenure

Dr. Akash Mathur has been Chief Executive Officer at Bal Pharma Limited since September 1, 2016. Dr. Mathur served as the Chief Business Officer of SignalChem Lifesciences Corporation since December 20, 20 ...


Board Age and Tenure

7.3yrs

Average Tenure

53yo

Average Age

The tenure for the Bal Pharma board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Shailesh Siroya (53yo)

    MD & Executive Director

    • Compensation: 7.80m
  • Subba Prasanna (71yo)

    Whole Time Director

    • Compensation: 3.00m
  • Archana Mitra (45yo)

    Vice President of International Marketing and Marketing Professional

  • M. George

    Production Advisor

  • Akash Mathur

    Chief Executive Officer

    • Tenure: 2.9yrs
  • Ravindra Kothari (64yo)

    Deputy General Manager of Internal Audit

  • Nabjit Sharma (40yo)

    General Manager of International Marketing

  • A.N.V.K Chaitanya

    Chief Financial Officer

    • Tenure: 0.9yrs

Board Members

  • Shailesh Siroya (53yo)

    MD & Executive Director

    • Tenure: 21.9yrs
    • Compensation: 7.80m
  • Subba Prasanna (71yo)

    Whole Time Director

    • Tenure: 25.0yrs
    • Compensation: 3.00m
  • S. Kumar (51yo)

    Independent Non-Executive Director

    • Tenure: 7.3yrs
    • Compensation: 8.00k
  • Premchand Bhantia Bhandari (51yo)

    Additional Independent Director

    • Tenure: 4.4yrs
    • Compensation: 8.00k
  • C.V. Srinivas (53yo)

    Additional Independent Director

    • Tenure: 0.2yrs

Company Information

Bal Pharma Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bal Pharma Limited
  • Ticker: BALPHARMA
  • Exchange: NSEI
  • Founded: 1987
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: ₹571.147m
  • Shares outstanding: 14.17m
  • Website: Click here

Location

  • Bal Pharma Limited
  • Lakshmi Narayan Complex
  • 5th Floor
  • Bengaluru
  • Karnataka
  • 560052
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524824BSE (Mumbai Stock Exchange)YesEquity SharesININRJan 2002
BALPHARMANSEI (National Stock Exchange of India)YesEquity SharesININRJan 2002

Biography

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC produ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company AnalysisN/A
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.